Woodline Partners LP acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE: TMO – Get Rating) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 17,953 shares of the medical research company stock, valued at approximately $ 11,979,000.
A number of other large investors also recently added to or reduced their stakes in the stock. Patriot Financial Group Insurance Agency LLC boosted its position in Thermo Fisher Scientific by 1.9% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 799 shares of the medical research company stock valued at $ 457,000 after purchasing an additional 15 shares during the period. Karp Capital Management Corp boosted its position in Thermo Fisher Scientific by 0.5% during the 4th quarter. Karp Capital Management Corp now owns 3,195 shares of the medical research company stock worth $ 2,132,000 after acquiring an additional 17 shares during the period. Archer Investment Corp raised its stake in shares of Thermo Fisher Scientific by 1.3% in the 4th quarter. Archer Investment Corp now owns 1,317 shares of the medical research company stock worth $ 879,000 after buying an additional 17 shares in the last quarter. Deseret Mutual Benefit Administrators raised its stake in shares of Thermo Fisher Scientific by 2.7% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 647 shares of the medical research company stock worth $ 432,000 after buying an additional 17 shares in the last quarter. Finally, Mechanics Bank Trust Department raised its stake in shares of Thermo Fisher Scientific by 0.9% in the 4th quarter. Mechanics Bank Trust Department now owns 1,963 shares of the medical research company stock worth $ 1,310,000 after buying an additional 18 shares in the last quarter. Institutional investors and hedge funds own 87.48% of the company stock.
Shares of NYSE TMO opened at $ 514.76 on Thursday. The business’s 50-day moving average price is $ 552.61 and its two-hundred day moving average price is $ 579.64. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.56 and a quick ratio of 1.10. Thermo Fisher Scientific Inc. has a one year low of $ 465.93 and a one year high of $ 672.34. The company has a market capitalization of $ 201.51 billion, a P / E ratio of 26.84, a price-to-earnings-growth ratio of 1.79 and a beta of 0.83.
Thermo Fisher Scientific (NYSE: TMO – Get Rating) last issued its earnings results on Thursday, April 28th. The medical research company reported $ 7.25 EPS for the quarter, beating analysts’ consensus estimates of $ 6.17 by $ 1.08. Thermo Fisher Scientific had a return on equity of 25.33% and a net margin of 18.49%. The firm had revenue of $ 11.82 billion for the quarter, compared to the estimate consensus of $ 10.66 billion. During the same quarter in the previous year, the company posted $ 7.21 earnings per share. The business’s quarterly revenue was up 19.3% compared to the same quarter last year. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 22.7 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, July 15th. Stockholders of record on Wednesday, June 15th will be paid a dividend of $ 0.30 per share. The ex-dividend date is Tuesday, June 14th. This represents a $ 1.20 annualized dividend and a dividend yield of 0.23%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.26%.
A number of analysts have recently commented on TMO shares. Wells Fargo & Company downgraded Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and dropped their price target for the stock from $ 605.00 to $ 525.00 in a research note on Monday, April 25th. StockNews.com assumed coverage on Thermo Fisher Scientific in a research report on Thursday, March 31st. They set a “hold” rating on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $ 658.92.
In other news, COO Michel Lagarde sold 17,150 shares of the company stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $ 548.30, for a total transaction of $ 9,403,345.00. Following the completion of the sale, the chief operating officer now owns 15,758 shares in the company, valued at approximately $ 8,640,111.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Debora L. Spar sold 200 shares of the company stock in a transaction dated Monday, May 2nd. The stock was sold at an average price of $ 544.36, for a total value of $ 108,872.00. Following the sale, the director now owns 810 shares of the company stock, valued at approximately $ 440,931.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 42,561 shares of company stock valued at $ 23,557,413. 0.43% of the stock is currently owned by corporate insiders.
Thermo Fisher Scientific Profile: (Get Rating)
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Receive News & Ratings for Thermo Fisher Scientific Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.